Хайлтын үр дүнгүүд - Tim Heise

Үр дүнг сайжруулах
  1. 1
    The future of insulin therapy

    The future of insulin therapy -н Tim Heise

    Хэвлэсэн 2021
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  2. 2
    A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance

    A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance -н Hanne Haahr, Tim Heise

    Хэвлэсэн 2014
    Бүрэн текст авах Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  3. 3
    Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes

    Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes -н Tim Heise, Chantal Mathieu

    Хэвлэсэн 2016
    Бүрэн текст авах Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  4. 4
    Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences

    Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences -н Hanne Haahr, Tim Heise

    Хэвлэсэн 2019
    Бүрэн текст авах Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  5. 5
    Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies

    Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies -н Tim Heise, Kadriye Kaplan, Hanne Haahr

    Хэвлэсэн 2017
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  6. 6
    A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use

    A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use -н Hanne Haahr, Edmond G. Fita, Tim Heise

    Хэвлэсэн 2016
    Бүрэн текст авах Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  7. 7
    How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes

    How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes -н Sabine Arnolds, B. Kuglin, Christoph Kapitza, Tim Heise

    Хэвлэсэн 2010
    Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  8. 8
    Common Standards of Basal Insulin Titration in T2DM

    Common Standards of Basal Insulin Titration in T2DM -н Sabine Arnolds, Tim Heise, Frank Flacke, Jochen Sieber

    Хэвлэсэн 2013
    Бүрэн текст авах Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  9. 9
    Impact of Diabetic Nephropathy on Pharmacodynamic and Pharmacokinetic Properties of Insulin in Type 1 Diabetic Patients

    Impact of Diabetic Nephropathy on Pharmacodynamic and Pharmacokinetic Properties of Insulin in Type 1 Diabetic Patients -н Klaus Rave, Tim Heise, Andreas Pfützner, Lutz Heinemann, Peter T. Sawicki

    Хэвлэсэн 2001
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  10. 10
    How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device

    How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device -н Carsten Benesch, Tim Heise, Oliver Klein, Lutz Heinemann, Sabine Arnolds

    Хэвлэсэн 2015
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  11. 11
    Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double‐blind, crossover trial

    Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, doub... -н Tim Heise, Eric Zijlstra, Leszek Nosek, Tord Rikte, Hanne Haahr

    Хэвлэсэн 2016
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  12. 12
    Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes

    Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes -н Tim Heise, Leszek Nosek, Susanne Gammelgaard Bøttcher, H. Hastrup, Hanne Haahr

    Хэвлэсэн 2012
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  13. 13
    Improvement of insulin resistance after diet with a whole-grain based dietary product: results of a randomized, controlled cross-over study in obese subjects with elevated fasting blood glucose

    Improvement of insulin resistance after diet with a whole-grain based dietary product: results of a randomized, controlled cross-over study in obese subjects with elevated fasting... -н Klaus Rave, Kerstin Roggen, Sibylle Dellweg, Tim Heise, Heike tom Dieck

    Хэвлэсэн 2007
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  14. 14
    A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes

    A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes -н Tim Heise, Thomas R. Pieber, Thomas Danne, Lars Erichsen, Hanne Haahr

    Хэвлэсэн 2017
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  15. 15
    Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels

    Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels -н Helga Blauw, I. Wendl, J. Hans DeVries, Tim Heise, Thomas Jax

    Хэвлэсэн 2015
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  16. 16
    Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus

    Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus -н Tim Heise, Leszek Nosek, Carsten Roepstorff, Suresh Chenji, Oliver Klein, Hanne Haahr

    Хэвлэсэн 2014
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  17. 17
    Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.

    Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. -н L Heinemann, R. Linkeschova, Klaus Rave, B. Hompesch, M Sedlak, Tim Heise

    Хэвлэсэн 2000
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  18. 18
    Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes

    Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes -н Christoph Kapitza, Eric Zijlstra, Lutz Heinemann, Mariacristina Castelli, Gary Riley, Tim Heise

    Хэвлэсэн 2010
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  19. 19
    Insulin degludec: <scp>L</scp>ower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 <scp>U</scp>/<scp>mL</scp> in type 1 diabetes

    Insulin degludec: <scp>L</scp>ower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 <scp>U</scp>/<scp>mL</scp> in type 1 diabete... -н Tim Heise, Marianne S. Nørskov, Leszek Nosek, Kadriye Kaplan, Susanne Famulla, Hanne Haahr

    Хэвлэсэн 2017
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  20. 20
    Faster‐acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart

    Faster‐acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart -н Tim Heise, Ulrike Hövelmann, Lise Brøndsted, Charlotte L. Adrian, Leszek Nosek, Hanne Haahr

    Хэвлэсэн 2015
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:

Хайх хэрэгслүүд: